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ABSTRACT
Quiescin sulfhydryl oxidase 1 (QSOX1) is a highly conserved disulfide  bond-
generating enzyme that is overexpressed in diverse tumor types. Its enzymatic 
activity promotes the growth and invasion of tumor cells and alters extracellular 
matrix composition. In a nude mouse-human tumor xenograft model, tumors 
containing shRNA for QSOX1 grew significantly more slowly than controls, suggesting 
that QSOX1 supports a proliferative phenotype in vivo. High throughput screening 
experiments identified ebselen as an in vitro inhibitor of QSOX1 enzymatic activity. 
Ebselen treatment of pancreatic and renal cancer cell lines stalled tumor growth 
and inhibited invasion through Matrigel in vitro. Daily oral treatment with ebselen 
resulted in a 58% reduction in tumor growth in mice bearing human pancreatic tumor 
xenografts compared to controls. Mass spectrometric analysis of ebselen-treated 
QSOX1 mechanistically revealed that C165 and C237 of QSOX1 covalently bound to 
ebselen. This report details the anti-neoplastic properties of ebselen in pancreatic and 
renal cancer cell lines. The results here offer a “proof-of-principle” that enzymatic 
inhibition of QSOX1 may have clinical relevancy. 
INTRODUCTION
QSOX1 is a highly conserved FAD-dependent 
sulfhydryl oxidase that catalyzes disulfide bond formation 
in reduced proteins and sulfhydryl-containing small 
molecules. QSOX1 has been reported to be overexpressed 
in diverse tumor types such as pancreatic [1, 2], breast 
[3, 4], and prostate cancers [5], and is associated with a 
proliferative and invasive phenotype [2, 3, 6]. QSOX1 
expression is not detected in normal breast tissue and is 
positively correlated with high grade breast tumors by 
transcriptomic analyses of EST and SAGE databases, as 
well as quantitative PCR of cDNA isolated from normal 
and malignant breast tissue [4]. Increased QSOX1 
expression in luminal B breast cancers predicts poor 
overall and relapse-free survival [3]. QSOX1 RNA is 
elevated when expression of the transcriptional regulator 
NKX3.1 is reduced in prostatic intraepithelial neoplasia 
[5], suggesting that QSOX1 expression may contribute to 
prostate cancer progression.
The predominant isoforms of QSOX1, QSOX-L 
(long, 742a.a.) and QSOX1-S (short, 604a.a.) have 
intra- and extracellular functions related to growth, 
invasion, and extracellular matrix structure and 
function. In pancreatic and breast cancer cell lines, 
QSOX1 expression is associated with a highly invasive 
phenotype and the increased activation of matrix 
metalloproteinase -2 and -9 [2, 3]. QSOX1 is required 
for the proper incorporation of laminin α4 subunits into 
the extracellular matrix (ECM), and reducing QSOX1 
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expression decreases cell adhesion and increases 
sulfhydryls in the ECM [7].
Here we report that QSOX1 expression contributes 
to tumor growth in an in vivo pancreatic tumor cell 
xenograft model, supporting QSOX1 as a potential 
molecular therapeutic target. A high-throughput screen of 
the small molecule LOPAC1280 library identified ebselen 
as a inhibitor of QSOX1 enzymatic activity in vitro. In 
this study, we investigate the biological effects of QSOX1 
inhibition and demonstrate, mechanistically, how ebselen 
suppresses QSOX1 activity.
RESULTS
QSOX1 expression drives increased tumor 
growth in vivo
We hypothesized that suppressing QSOX1 levels 
in tumors expressing shRNAs specific for QSOX1 would 
slow their growth compared untreated and scrambled 
shRNA control (shScr) cells. Tumors containing QSOX1 
shRNAs (sh742 or sh528) grew at a reduced rate compared 
to shScr control xenografts (Figure 1A). Tumor masses on 
day 28 of the experiment showed that tumor growth was 
reduced by 77% in tumors transduced with sh742, and 
by 48% in tumors transduced with sh528 compared to 
shScr tumors (Figure 1B, 1C). These results indicate that 
QSOX1 expression promotes tumor growth in vivo and 
suggest that QSOX1 could be a target for potential anti-
neoplastic compounds.
Ebselen inhibits rQSOX1 activity in vitro
We used a sulfhydryl activity assay similar to the 
one developed by Colin Thorpe’s group [8] to screen 
recombinant QSOX1 against a library of pharmacologically 
active compounds, LOPAC1280. In this enzymatic assay 
(Supplementary Figure S1A), rQSOX1 oxidizes a reduced 
RNAse A or DTT substrate, producing H
2
O
2
 detected by a 
luminescent reaction. In the presence of a QSOX1 inhibitor, 
the sulfhydryl oxidase activity of QSOX1 is blocked, 
preventing disulfide bond formation and H
2
O
2
 production. 
The relative inhibitory activity of LOPAC1280 is plotted 
in Figure S1B. We identified ebselen (Figure S1C) as an 
inhibitor of QSOX1 enzyme activity, with greater inhibitory 
activity against QSOX1 than GOx (Figure S1D); the IC
50
 
for ebselen inhibition of QSOX1 and GOx was determined 
to be 5.4 μM and 20.5 μM, respectively. Confirmation of 
ebselen’s inhibitory activity was obtained by HyPerBlu 
luminescent detection (Figure S1D, middle plot) and HVA-
based fluorescent assays showing decreased fluorescence as 
inhibitor concentration increases (Figure S2).
Ebselen reduces tumor cell invasion
One of the fundamental properties of malignant cells 
leading to metastatic disease is invasion. Since ebselen 
inhibits QSOX1, we hypothesized that it would suppress 
invasion of tumor cells similar to shRNA-mediated 
knockdown of QSOX1.
MIAPaCa-2, BXPC3, 786-O, and UOK117 cells 
were incubated in matrigel-coated invasion chambers in 
serum-free media in the presence of ebselen or vehicle. 
Invading cells were quantified after 20 hours (Figure 2). 
Isogenic MIAPaCa-2 lines were generated that express 
shRNAs specific for QSOX1 (sh742 and sh528) or a 
nonspecific sequence (shScr) (Figure 2A). shScr cells 
exposed to 5 μM – 15 μM ebselen showed decreased 
invasion compared to DMSO vehicle-treated cells, with 
reductions of 91%, 94%, and 98%, respectively. sh742 
cells showed greater than 60% decreased invasion 
compared to shScr cells. Invasion was rescued to levels of 
vehicle-treated shScr wells when 50 nM active rQSOX1 
was added to sh742 wells at the initiation of the assay 
(Figure 2A, sixth bar). rQSOX1 pre-incubated with 
15 μM ebselen and then added to sh742 cells, however, 
did not rescue invasion. These results suggest that one of 
Figure 1: Growth of MIAPaCa-2 tumors over 28 days in nude mice. A. Growth kinetics of MiaPaca-2 tumors with QSOX1 
knockdowns (sh742 triangles, sh528 circles), scrambled control (squares), or untreated (diamonds). B. Final tumor masses on day 28. 
C. Images of shScr (top), sh528 (middle), or sh742 (bottom) tumors dissected from mice on day 28. Significance was determined by T-test; 
knockdowns were compared to vehicle-treated tumors. *p < 0.05. Bar = 3 mm.
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Figure 2: Ebselen inhibits invasion of pancreatic and renal cell cancer cell lines through a Matrigel basement 
membrane. A. Isogenic MIAPaCa-2 cell lines transduced with a QSOX1-specific shRNA (sh742) or a nonspecific sequence (shScr) 
were incubated for 20 hours in invasion well inserts; cells were exposed to 5–15 uM ebselen or vehicle +/- 50 nM rQSOX1 (sh742 only). 
Invasion of B. BXPC3, C. 786-O, and D. UOK117 cells exposed to ebselen or vehicle. Vehicle was 0.15% DMSO. Error bars represent 
SEM. For A significance for ebselen-treated shScr cells was calculated for vehicle-treated shScr cells. For sh742 cells, significance is 
relative to sh742 cells treated with rQSOX1 alone. Statistical significance was determined by T-test. *p < 0.05, **p < 0.01.
the mechanisms by which ebselen suppresses invasion is 
through QSOX1 inhibition.
We also quantified invasion in ebselen-treated 
BXPC3, 786-O, and UOK117 cells (Figure 2B-2D). 
Ebselen suppressed invasion in these tumor cell lines in 
a concentration-dependent manner. At 5 μM, BXPC3 
invasion was reduced by 85%, 89% for 786-O, and 40% 
for UOK117. 10 μM ebselen treatment decreased BXPC3, 
786-O, and UOK117 invasion by 95%, 97%, and 80% 
compared to vehicle-treated cells, respectively. Near total 
inhibition of invasion was observed for each cell line 
treated with 15 μM ebselen. These results were statistically 
significant in BXPC3 and UOK117 with p-values calculated 
at < 0.05. Results for 786-O were not statistically significant 
(p = 0.08 – 0.09), but show a similar dose-response.
Ebselen reduces tumor growth in vivo
Nude mice subcutaneously injected with MIAPaCa-2 
cells were treated for 28 days with ebselen by oral gavage 
at two clinically achievable doses to determine if ebselen 
suppresses tumor growth in vivo. As shown in Figure 3, 
daily treatment with ebselen at both high (640 μg) and low 
(160 μg) doses suppressed tumor growth in MIAPaCa-2 
nude mouse xenografts. There was no difference in tumor 
size between high and low doses, but tumors in mice treated 
with 160 μg ebselen were ~56% smaller than vehicle-
treated mice at day 28. There was no difference in the 
average mouse weights between the vehicle and ebselen-
treated groups (Figure S3), suggesting that the observed 
difference in tumor growth were not due decreased appetite 
or decreased nutrient absorption in ebselen-treated mice. 
Taken together, these results suggest that ebselen decreases 
tumor growth in vivo.
Ebselen covalently binds to QSOX1
Ebselen is reactive with reduced cysteines through 
the formation of a Se-S bond with target sulfhydryls [9]. We 
therefore hypothesized that ebselen covalently binds with 
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Figure 3: Ebselen treatment of nude mice bearing human tumors. A. One million MIAPaCa2 cells were mixed with Matrigel 
and used to inoculate nude mice (5 mice/group) on day 0. Mice were gavaged daily starting on day 3 with vehicle (20% DMSO, open 
circle), 160 μg/day ebselen (filled square) or 640 μg/day ebselen (filled triangle) in DMSO. Tumor measurements are shown for days 3, 6, 
10, 13, 18, 22 and 28. Tumor volume is shown on the Y-axis and time in days is shown on the X-axis. Significance was determined by 
two-way ANOVA with Dunnet’s Test used to correct for multiple comparisons compared to vehicle-treated mice. *p < 0.05, **p < 0.01, 
***p < 0.001. B. Representative tumors from vehicle-treated and ebselen-treated mice. Bar = 2 mm.
Figure 4: Ebselen binds covalently to rQSOX1 at cysteine residues. A. Charge deconvoluted ESI-LC-MS spectra of rQSOX 
(top spectrum) in the absence of substrate, rQSOX1 treated with 5 μM ebselen (middle spectrum), and rQSOX1 treated with 5 μM ebselen 
in the presence of DTT substrate (bottom spectrum). The mass of an ebselen adduct is 274.18 Da. The left shaded column indicates the 
mass range of unmodified rQSOX1. Peak A is the mass of rQSOX1 without the N-terminal methionine and peak B is the mass of rQSOX1 
with N-acetyl Met. The middle shaded column represents the mass of rQSOX1 with a single bound ebselen molecule with peaks labeled 
A+1Eb and B+1Eb. The right shaded column represents the mass of rQSOX1 with two ebselen adducts (A+2Eb and B+2Eb). B. QSOX1 
pretreated with ebselen blocks the binding of fluoresceinated maleimide. A 5-fold molar excess of ebselen was added to 5 μg rQSOX1 prior 
to maleimide addition. UV imaging of SDS-PAGE gels show that maleimide binding to rQSOX1 is blocked by the addition of ebselen.
cysteines in QSOX1, which would suggest a mechanism 
for the inhibition of enzymatic activity. The formation of 
ebselen adducts would be expected to increase the mass of 
QSOX1 by the molecular weight of one or more ebselen 
molecules, 274.18 Da. We performed LC-MS analysis 
on untreated or ebselen-treated rQSOX1 in the presence 
or absence of DTT (an established substrate for QSOX1) 
[8, 10, 11] (Figure 4A). Untreated rQSOX1 (Figure 4A, 
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top spectrum) displays two prominent peaks with masses of 
58683 and 58860 Da, designated “A” and “B,” respectively, 
corresponding to two post-translationally modified forms of 
rQSOX1.
Treatment of QSOX1 with ebselen shows a mass 
shift corresponding to two ebselen adducts per peak 
(Figure 4A, middle spectrum). In the bottom spectrum 
of Figure 4A, rQSOX1 was also treated with ebselen in 
the presence of DTT substrate. The masses of unmodified 
rQSOX and rQSOX1 containing 1 or 2 ebselen molecules 
were detected simultaneously, suggesting that DTT can 
remove ebselen from QSOX1.
We performed a protection assay (Figure 4B), 
blocking free cysteines in QSOX1 with ebselen 
pre-treatment followed by incubation with the 
thiol-reactive compound maleimide. Vehicle-
treated rQSOX1 showed strong fluorescence at the 
expected MW of 58.8 kDa, but ebselen pre-treatment 
decreased resting QSOX1 fluorescence by > 94%. These 
results suggest that ebselen binds to free cysteines in 
resting QSOX1.
Identification of ebselen-binding 
cysteines in QSOX1
We employed a cyanylation strategy to identify 
ebselen-binding cysteines in resting QSOX1, utilizing 
the reagent 1-cyano-4-dimethylaminopyridinium 
tetrafluoroborate (CDAP). CDAP cyanylates free, but not 
disulfide-bound, cysteines in proteins; they are then cleaved 
on the amino side of the CDAP-cysteine adduct when 
subjected to alkaline conditions [12–15]. MALDI analysis 
of CDAP-treated, cleaved and reduced rQSOX1 revealed 
3 unique cleavage fragments (Figure 5A). Fragments 
1, 2, and 3 had observed masses of 15668, 8063.1, and 
35242 Da, respectively (black arrows in Figure 5A). 
These masses correspond to cleavage with the expected 
iminothiazolidine formation [12–15] on the N-terminal 
side of cysteines 165 and 237 in QSOX1 as shown in the 
diagram in Figure 5B. Predicted versus observed molecular 
weights for these cleavage products are shown in Figure 5C. 
The cyanyl group increases fragment masses by 25 Da 
(fragments 2 and 3).
DISCUSSION
QSOX1 is an emerging target in tumor biology 
given its roles in cell growth, invasion, and the regulation 
of extracellular matrix composition [2–4, 7, 11, 16]. 
Secreted QSOX1 acts directly in the extracellular 
matrix to enhance tumorigenic processes through poorly 
understood mechanisms. Inhibition of QSOX1 activity 
in the clinic has the potential to decrease the growth and 
invasion of tumors, possibly containing primary growths 
and increasing survival.
Here we establish that QSOX1 promotes tumor 
growth in vivo, strengthening the connection between 
elevated QSOX1 expression and tumor aggression 
[3–5]. Xenografted MIAPaCa-2 tumors with stable 
QSOX1 knockdowns grew at significantly reduced rates 
compared to controls (Figure 1). These data support 
other studies demonstrating a pro-tumorigenic role for 
QSOX1 [2–7, 11, 16].
Figure 5: Identification of ebselen-binding cysteines in QSOX1. A. Cyanylated rQSOX was cleaved by NH
3
 treatment and 
reduced with TCEP. Analysis by MALDI-MS identified two cleavage sites that produced QSOX1 fragments with masses of 15 668 Da 
(Fragment 1), 8 063.1 Da (Fragment 2), and 35 242 Da (Fragment 3). The top and bottom spectra panels in (blue) show untreated (blue) 
and CDAP-treated (red) QSOX1 peaks, respectively. Arrows indicate unique peaks appearing in CDAP-treated, but not untreated, rQSOX1 
samples. B. Mapped QSOX1 CDAP cleavage fragments. Peak masses correspond to cysteines 165 and 237 in wild-type QSOX1. Cyanyl 
groups are depicted as white diamonds. Three redox-active C-X-X-C pairs are shown disulfide bonded. The four remaining disulfide-
bonded cysteines are not shown. Cleavage of rQSOX1 by ammonia (black scissors) produced the three CDAP fragments observed in A. 
C. Predicted and observed average m/z for cleavage at residues C165 and C237. The predicted masses for fragments 2 and 3 include an 
additional 25 Da from the cyanyl group.
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The enzymatic activity of QSOX1 is essential 
for its roles in invasion and regulation of extracellular 
matrix composition [3, 7]. An inhibitory antibody 
recently developed blocks QSOX1 activity and reduces 
the invasion of tumor cells across a fibroblast monolayer 
[7], supporting the idea that directly targeting QSOX1 
enzyme activity has anti-invasive properties. Thus, small 
molecule inhibition of QSOX1 may have therapeutic 
efficacy or reveal novel pathways in QSOX1 biology.
In a high throughput screen of the LOPAC1280 
chemical library utilizing recombinant QSOX1, we 
identified ebselen as an inhibitor of QSOX1 enzyme 
activity. We used Aspergillus niger glucose oxidase 
(GOx) as a general counter-screen to ensure that 
inhibition was specific for QSOX1. Although both GOx 
and QSOX1 contain FAD as a cofactor, the former uses 
FAD as the initial electron acceptor [17], while FAD 
serves as terminal electron acceptor in the QSOX1 
Erv1 domain. In addition, the sequence and structure 
of the two proteins are very different [18], sharing only 
20% sequence identity. Thus the majority of genuine 
inhibitors are expected to show strong preference for 
QSOX1. As seen in supplementary Figure S1D, GOx 
is inhibited by ebselen only at a concentration 4-fold 
higher than was observed for QSOX1.
Since ebselen reacts with free cysteines and 
both QSOX1 substrates and its own redox activity are 
dependent on sulfhydryls, we were initially concerned 
that the interaction of ebselen with QSOX1 substrates 
DTT and RNAse A might make ebselen appear to inhibit 
QSOX1 spuriously through substrate depletion. We used 
between 150 and 2400-fold molar excesses of substrate 
thiols over ebselen in confirmatory activity assays to guard 
against this possibility (Figure S2). If the interaction of 
ebselen with substrate was extensive, even with total 
exhaustion of ebselen sufficient unreacted substrate would 
be available for QSOX1 oxidation. These conditions 
would allow for near-maximum signal to be detected, 
preventing the identification of compounds with an 
indiscriminate preference for free cysteines. Additionally, 
rQSOX1 enzyme was always added last to reactions such 
that ebselen was present with substrate before QSOX1 
addition. Therefore, the excess substrate would deplete 
available ebselen prior to the addition of active enzyme.
Ebselen treatment of tumor cell lines resulted in 
significantly decreased invasion in trans-well invasion 
assays compared to DMSO vehicle-treated cells (Figure 2). 
These results are consistent with decreased invasion 
in cells expressing QSOX1-specific shRNAs [2, 3, 7]. 
Importantly, rescue of invasion in QSOX1-knockdown 
cells was achieved with the addition of 50 nM exogenous 
recombinant QSOX1 enzyme (Figure  2A, fifth bar). 
However, pre-incubation of recombinant enzyme with 
15 μM ebselen prior to addition of QSOX1 to tumor cells 
did not restore invasive activity (Figure 2A, sixth bar), 
suggesting that ebselen inactivates QSOX1. In fact, tumor 
cell invasion was further decreased compared to the sh742 
knockdowns, underscoring the incomplete suppression of 
gene expression using a shRNA system. These results 
indicate that one mechanism by which ebselen decreases 
tumor cell invasion is via QSOX1 enzymatic inhibition.
We investigated the growth modulatory effects 
of ebselen in pancreatic and kidney cancer cell lines 
(Figure S4). Ebselen was a poor inhibitor of growth in 
kidney cancer cell lines, but did significantly inhibit 
growth of pancreatic cell line MIAPaCa-2 at 10 μM 
and 15 μM and BXPC3 at 15 μM. QSOX1 expression 
was similar for the cell lines tested by western 
blotting (Figure S5), thus QSOX1 expression alone 
fails to explain the growth effects observed. Viability 
determinations showed that ebselen is not cytotoxic to 
tumor cells (Figure S6), so decreased growth is therefore 
attributable to reduced proliferation. Ebselen treatment 
also causes tumor cells to “round up” (data not shown). 
While anecdotal, this observation is consistent with the 
morphological changes observed when QSOX1 expression 
is suppressed by shRNAs [2, 3].
Incubation of 15 μM ebselen with normal 
lymphocytes and non-malignant fibroblasts does not result 
in toxicity (~98% viability after 48 hours, data not shown). 
Additionally, ebselen has an established safety profile and 
dosing in humans in phase II clinical trials for cerebral 
infarct [19–21]. Patients in this 1998 clinical trial who 
received ebselen had no statistical increase in adverse 
events compared to placebo groups for new cerebral 
infarction, new hemorrhagic infarction, gastrointestinal 
bleeding, nausea/vomiting, or respiratory infection. The 
authors also note that ebselen treatment did not contribute 
to the death of any patient [21].
Daily oral gavage of ebselen in human pancreatic 
tumor xenografts resulted in slower tumor growth than 
vehicle controls. Ebselen appears to suppress invasion 
and is not directly cytotoxic, but none-the-less affects 
human pancreatic tumor cell growth in vivo as shown 
in Figure 3. While both low (160 μg/day) and high 
(640 μg/day) doses of ebselen decreased tumor growth 
in our xenograft model, we did not observe differences 
in tumor volume between dosages. There may be no 
additional benefit to treatment with higher doses of ebselen 
beyond a certain threshold. Ebselen treatment did not 
cause weight loss, independent of tumor size (Figure S3). 
While the mechanism of decreased tumor cell growth with 
ebselen treatment may be unclear, one explanation for the 
decrease in tumor growth in treated mice is inhibition 
of QSOX1 activity in the extracellular matrix. QSOX1 
is required for incorporation of laminin α4 chains in the 
ECM [7]. Its inhibition may limit the ability of tumor cells 
to modify the ECM to promote tumor growth. QSOX1 
also activates MMP-2 and -9, supporting the role of 
QSOX1 in forming a pro-tumorigenic microenvironment.
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Ebselen is a heterocyclic selenoorganic compound 
first identified as a glutathione peroxidase mimic and 
scavenger of organic hydroperoxides [22–24]. The 
intriguing enzyme-like activity of ebselen forms the basis 
for its pharmacological effects [25, 26] that include potent 
antioxidant and anti-inflammatory properties [9, 27]. 
Ebselen covalently binds to thiols and this has emerged 
as a mechanism for its activity [28]. Ebselen reacts via 
reduction of the Se-N bond in the selenazole ring structure, 
forming a sulfur-selenium bond with target cysteines [29]. 
We show that ebselen inhibits QSOX1 activity through 
covalent modification of non-redox cysteines C165 and 
C237 in the extant thioredoxin-2 domain.
Crystal structures of human rQSOX1 show that its 
cysteines exist as disulfide pairs in the resting enzyme 
except for cysteines 165 and 237 [30, 31]. How ebselen 
inhibits QSOX1 through interaction with these residues is 
unclear because they are not thought to participate in the 
accepted disulfide relay mechanism. There is no evidence 
supporting cysteines other than the redox-active C-X-X-C 
motifs in the Trx1 and Erv domains as contributing to 
QSOX1 activity [11, 18, 32–34]. C237 is likely protonated 
and relatively inert to redox reactions since there are no 
nearby basic residues to stabilize a thiolate anion [35]. 
The location of C165 in a predicted disordered region of 
QSOX1 between the Trx1 and Trx2 domains, however, 
may allow for interactions with nearby basic resides [31]. 
A recently described mechanism proposes that the flexible 
domain architecture of QSOX1 is critical in allowing Trx1 
to come into close contact with Erv to transfer electrons to 
the C-X-X-C in this domain [30, 36]. Ebselen bound to 
C165 and C237 may interfere with the conformational 
change required for the interaction of the Trx1 and Erv 
domains. Another possibility is that these cysteines 
modulate the activity of QSOX1; C165 is conserved 
in QSOX1 among vertebrates but not invertebrates 
(Figure S7) and may have evolved as a mechanism 
to regulate QSOX1 function. Further enzymatic and 
structural studies will address these hypotheses.
We have provided evidence that inhibition of QSOX1 
activity by ebselen leads to significantly decreased invasion 
of tumor cell lines in vitro and reduced tumor growth in vitro 
and in vivo, effects comparable to QSOX1 knockdown. 
Since metastasis is the cause of most cancer deaths, even 
partially suppressing invasive processes through QSOX1 
inhibition may help prolong survival. This study further 
establishes QSOX1 as a tractable target for anti-neoplastic 
drugs. Future studies will identify more potent and specific 
inhibitors of QSOX1 that may decrease metastasis in vivo.
MATERIALS AND METHODS
Cell culture
All cells were cultured in a humidified incubator 
at 37°C with 5% CO
2
. Media was supplemented with 
5% fetal bovine serum (Gibco, Carlsbad, CA USA) and 
100 μg/ml penicillin/streptomycin (Gibco) Pancreatic 
tumor cell lines MIAPaCa-2 and BXPC3 were maintained 
in Dulbecco’s Modified Eagle Medium (DMEM), (Gibco). 
Renal cancer cell line 786-O was cultured in RPMI 1640 
(MediaTech, Manassas, VA USA). Renal cancer cell line 
UOK117 was cultured in DMEM, supplemented with 
1X MEM nonessential amino acids (Mediatech). 786-O 
cells were cultured from frozen stocks purchased from 
Sigma-Aldrich and were authenticated by STR analysis 
after thawing. UOK117 cells were received from the 
Linehan laboratory at the National Cancer Institute 
and experiments performed from early passage stocks. 
MIAPaCa-2 and BXPC3 cells were cultured from frozen 
stocks that underwent independent STR testing 12/2012.
QSOX1 knockdown
Lentiviruses packaged with short hairpin RNA 
(shRNA) constructs specific for human QSOX1 
(sh528, sh742) or a nonspecific scrambled sequence 
(shScr) were produced in 293T cells as reported 
by Katchman et al. [2]. Knockdown of QSOX1 in 
MIAPaCa-2 was confirmed by western blotting using anti-
QSOX1 antibody (Protein Tech, Chicago, IL USA).
Nude mouse-human tumor xenograft model
Stably transduced MIAPaCa-2 cells (shScr, sh742, 
and sh528) were harvested from subconfluent cultures 
after brief exposure to Cell Stripper (Corning, Corning 
NY). Cell suspensions were counted, washed once in 
ice cold serum-free RPMI and resuspended in cold 1x 
PBS. 2.4 × 107 total cells were mixed in a 1:1 ratio with 
Matrigel (BD Biosciences) according to manufacturer 
specifications. Cells were kept on ice throughout the 
procedure. Female athymic Foxn1nu mice (Harlan, 
Indianapolis, IN USA) were injected with 1 × 106 
MIAPaCa-2 cells in Matrigel. Mice were housed in a 
barrier facility on HEPA-filtered racks. All experiments 
were conducted with strict adherence to aseptic technique 
and IACUC regulations. Each mouse was subcutaneously 
injected with 200 μl of cell suspension into the right hind 
flank using a 21-gauge needle. Mice were examined every 
other day to determine the volume of the tumor using 
calibrated calipers. Real-time tumor volume was measured 
as V = 0.5 × length × width2. When the tumors reached a 
volume of 1500–2000 mm3 the mice were sacrificed and 
the tumor was excised, measured and weighed.
For ebselen treatment of nude mice, three groups 
were tested: 1) 20% DMSO (vehicle), 2) 160 μg/day 
ebselen, and 3) 640 μg/day ebselen. 160 and 640 μg 
ebselen represent an equivalent dose of 150mg and 600mg 
for a 70 kg human, respectively. 1x106 MIAPaCa-2 cells 
were injected subcutaneously into each mouse as before, 
and tumors were allowed to grow for 3 days. Ebselen 
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was then administered once daily through oral gavage 
for 28 days. Real-time tumor volume was determined 
through caliper measurement of tumors over the course 
of the study [37]. Error is represented as SEM. Statistical 
significance was determined using two-way analysis 
of variance (ANOVA), comparing drug-treated with 
vehicle-treated mice. Corrections for multiple comparisons 
were made using Dunnett’s Test.
rQSOX1 expression and purification
rQSOX1 was produced and purified according 
to the method of Heckler [32]. Rosetta-gami B (DE3) 
cells (Novagen, Billerica MA USA) were transformed 
with 50 ng pET15b containing truncated QSOX1-S. The 
rQSOX1 construct contains an N-terminal poly-histidine 
tag and encodes amino acids 33–546 of QSOX1-S. The 
activity of the recombinant enzyme verified as described 
below using a dithiothreitol (DTT) substrate [8]. The 
elution profile for rQSOX1 and MALDI/LC-MS2 analysis 
of trypsin-digested rQSOX are shown in Supplementary 
Figures S8 and S9, respectively.
rQSOX1 small molecule screen
A HTS assay was developed using reduced 
denatured RNAse A substrate [38]. Hydrogen peroxide 
produced in the QSOX1 reaction was detected using 
ROS-Glo kit (Promega, Madison WI) as a primary 
assay and HyPerBlu (Lumigen, Southfield MI) as a 
secondary assay per manufacturers instructions. Assays 
were optimized and reaction kinetic parameters were 
determined. The assays were miniaturized to final volume 
of 2 uL. HTS was also performed using the ROS-Glo 
assay with a substrate concentration of 80 uM RNAse A 
(that is close to K
m
 value of 122 μM). rQSOX1 protein 
was utilized at 10 nM concentration, > 20-fold over the 
limit of assay detection yet still on the linear portion of 
the enzyme-dependent activity. rQSOX1 was screened 
against compounds from the LOPAC1280 library (Sigma-
Aldrich, St. Louis MO USA) at 12.5 μM compound 
concentration. Compounds that demonstrated > 50% 
inhibition were re-tested using single-concentration in 
triplicate wells, followed by concentration-dependent 
confirmation in the primary and secondary QSOX1 
assays. A luminescent assay for glucose oxidase (GOx) 
was used as a counter-screen. The GOx assay utilized 
glucose as a substrate was detected using ROS-Glo. 
Active and selective compounds were purchased in dry 
powder form, dissolved in DMSO and reconfirmed in the 
assays before use in the confirmatory assays utilizing the 
GOx counter-screen.
rQSOX1 activity assay
The sulfhydryl oxidase activity of rQSOX1 was 
confirmed using DTT and RNAse A substrates and a 
fluorogenic hydrogen peroxide indicator, homovanilic 
acid (HVA) [8]. In this assay, 150 nM rQSOX1 was added 
to 600 μM thiols from reduced DTT or RNAse A, 1 mM 
HVA, 1.4 μM HRP, and 300 μM EDTA in PBS at 25oC, 
pH 7.5. Assays were performed in black 96-well plates 
with a final reaction volume of 150 μl. Fluorescence 
signal was measured over 10 minutes at λex 320 nm 
and λ
em
 420 nm using a FlexStation spectrophotometer 
(Molecular Devices, Sunnyvale CA USA). Readings were 
taken in 20 second intervals after the addition of rQSOX1. 
Ebselen was added to reactions at least 10 minutes prior 
to the addition of rQSOX1 at concentrations ranging from 
250 nM – 4 μM.
Results for the HVA-based activity 
assay for rQSOX1 and ebselen are shown in 
Supplementary Figure S2.
Compound
2-phenyl-1, 2-benzisoselenazol-3(2H)-one, ebselen 
(Sigma-Aldrich), was dissolved in tissue culture-grade 
DMSO (Sigma-Aldrich, St. Louis, MO.) to a stock 
concentration of 10 mM and stored at –20°C protected 
from light.
Growth kinetics of ebselen-treated tumor cells
1 × 104 cells/well MIAPaCa-2, BXPC3, 786-O, and 
UOK1117 were plated in duplicate in 24-well plates. Cells 
were adhered overnight prior to the addition of fresh media 
(untreated), vehicle (0.15% DMSO), or 5 μM – 15 μM 
ebselen. Cells were counted using a hemacytometer and 
Trypan Blue exclusion to assess viability. Cells were 
counted on days 3 and 5, and “floaters” (disadhered 
and dead cells) were saved for determination of overall 
viability. Media was replaced on day 3 for the 5th day 
time point; floaters were saved and added back to 
each well for counting on day 5. Viability was determined 
as [1-(# dead cells / (# live cells + # dead cells))*100]. 
Error is represented as the standard error of the mean. 
Significance was determined using paired T-testing for 
each time point compared to vehicle-treated cells.
Trans-well invasion assays
2 × 104 MIAPaCa-2, BXPC3, 786-O, or UOK117 
cells were seeded in rehydrated 24-well invasion assay 
inserts containing 8 μm pores overlaid with Matrigel 
(Corning) in serum-free media; cells were adhered for 
1 hour prior to addition of ebselen or vehicle. Inserts 
were incubated in wells containing complete media for 
20 hours at 37oC. Non-invading cells were removed 
with cotton swabs and membranes were fixed with 
100% methanol and mounted on slides with DAPI 
(Life Technologies). The total number of invading cells 
was determined by manual counting of DAPI-stained 
nuclei.
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Electrospray ionization mass spectrometry
2 μM rQSOX1 was incubated with 20 μM ebselen 
(10-fold excess) with or without 10 μM DTT substrate 
(added 5 minutes prior to mass analysis).  rQSOX1 was 
analyzed intact by liquid chromatography-electrospray 
ionization-mass spectrometry (LC-ESI-MS) on a Dionex 
Ultimate 3000 HPLC equipped with a 1:100 flow splitter 
connected to a Bruker Maxis 4G quadrupole-time-of-
flight (Q-TOF) mass spectrometer.  A trap-and-elute 
form of LC-MS was carried out in which 15 µL samples 
were loaded at 10 μl/min in 80/20 water/acetonitrile 
containing 0.1% formic acid (loading solvent) 
onto a Bruker-Michrom protein captrap conFigured 
for bi-directional flow on a 6-port diverter valve.  The 
trap was then rinsed with the HPLC loading pump at 
10 µl/min for 40 min to completely remove PBS buffer 
salts.  The flow over the captrap was then switched 
to the micropump, set at 2 µL/min, and ramped over 
5 minutes from 80% water containing 0.1% formic 
acid (Solvent A)/20% acetonitrile (Solvent B) to 90% 
acetonitrile and held for 3 min.
The captrap eluent was directed to the mass 
spectrometer operating in positive ion, TOF-only mode, 
acquiring spectra in the m/z range of 300 to 3000 with 
a nominal resolving power of ~60, 000 m/ßm FWHM. 
ESI settings for the Agilent G1385A capillary microflow 
nebulizer ion source were as follows: End plate offset 
–500 V, capillary –3500 V, nebulizer nitrogen 2 bar, dry 
gas nitrogen 3.0 L/min at 225°C. Data were acquired in 
profile mode at a digitizer sampling rate of 4 GHz. Spectra 
rate control was by summation at 1 Hz.
rQSOX1 eluted over a period of about 1 minute; 
under the above conditions, rQSOX1 ranged in charge 
state from +32 to +60. Raw mass spectra were averaged 
across this timeframe, baseline subtracted and charge 
deconvoluted with Bruker DataAnalysis 4.1 charge 
deconvolution software to a mass range of 1000 Da on 
either side of any identified peak.
Maleimide protection assay
2 μM rQSOX1 in 1X PBS (pH 7.5) was incubated 
with a 5-fold molar excess of ebselen or vehicle 
for 5 minutes at 25oC. AlexaFluor488-C5-maleimide 
(Life Technologies, Carlsbad CA) was added to a final 
concentration of 100 μM. Reactions were incubated for 
30 minutes at 37oC, protected from light. Protein from 
each reaction was resolved on 12% polyacrylamide gels 
in non-reducing conditions. Gels were washed twice for 
5 minutes in ddH
2
O and imaged under UV light. Gels 
were then stained with Coomassie R-250 for 15 minutes. 
Band intensities were analyzed by ImageJ, and are 
represented as “percent signal” of rQSOX1 pre-incubated 
with vehicle.
Cyanylation and ammonia-based cleavage 
at free cysteines
Free cysteines on rQSOX1 were identified by 
treatment of recombinant enzyme with the sulfhydryl 
cyanylating reagent 1-Cyano-4-dimethylaminopyridinium 
tetrafluoroborate (CDAP) followed by ammonia-mediated 
N-terminal cleavage and analysis by MALDI-MS 
[39]. 100 pmol rQSOX1 was dissolved in 0.1 M citrate 
containing 6 M guanidine-HCl, pH 3.0. CDAP was added 
to a concentration of 25 mM from a freshly prepared 
200 mM stock and incubated for 15 minutes at 25oC. 
Trifluoroacetic acid (TFA) was added to a concentration 
of 0.2%, and protein was purified using C18 ZipTips 
(Millipore); purified rQSOX1 was eluted with 90% ACN 
with 0.1% TFA in MilliQ H
2
O. Samples were dried and 
reconstituted in 6 M guanidine-HCl containing 1 M 
NH
4
OH, pH 11.5. Samples were incubated for 60 minutes 
at 37oC. Reactions were quenched by reducing the pH 
to 3.0 with citric acid. Disulfide bonds were reduced in 
100 mM TCEP dissolved in ddH2O for 30 minutes at 
37oC. 0.2% TFA was added, and C18 ZipTip purification 
was repeated as before. Samples were eluted with 3 ul 
90% ACN/0.1% TFA directly onto MALDI targets; 2 μl 
saturated sinapinic acid in 33% ACN/0.4% TFA was added 
and samples air-dried.
MALDI mass spectrometry
Masses of cyanylation/ammonia-induced protein 
cleavage products of rQSOX1 were determined by 
MALDI-MS on a Bruker Ultraflex-III MALDI mass 
spectrometer equipped with a Nd:YAG laser operating 
in positive-ion, delayed extraction linear mode, with ion 
source 1 at 25.00 kV, ion source 2 at 23.10 kV, lens at 
7.50 kV, 150 ns delay, and 1 GS/s sample rate. Prior to 
acquisition of the mass spectra, the target mass range was 
externally calibrated using a mixture of calibrants obtained 
from Bruker Daltonics (Billerica, MA USA).
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